0001819790-21-000059.txt : 20211203 0001819790-21-000059.hdr.sgml : 20211203 20211203185658 ACCESSION NUMBER: 0001819790-21-000059 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211201 FILED AS OF DATE: 20211203 DATE AS OF CHANGE: 20211203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ackermann Michael CENTRAL INDEX KEY: 0001791249 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39614 FILM NUMBER: 211471530 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001819790 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 814717861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: (949) 409-9820 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 4 1 wf-form4_163857580594057.xml FORM 4 X0306 4 2021-12-01 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001791249 Ackermann Michael C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618 1 0 0 0 Common Stock 2021-12-01 4 S 0 2442 23.85 D 1207407 D Common Stock 2021-12-01 4 S 0 2054 24.68 D 1205353 D Common Stock 2021-12-01 4 S 0 809 25.87 D 1204544 D Common Stock 2021-12-01 4 S 0 528 26.65 D 1204016 D The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $23.24 to $24.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $24.28 to $25.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.51 to $26.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.53 to $27.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Leonard M. Greenstein, Attorney-in-Fact 2021-12-03